KLHDC10 Inhibitors
KLHDC10 inhibitors are a class of chemical compounds designed to specifically impede the activity of the KLHDC10 protein. This protein, encoded by the KLHDC10 gene, plays a crucial role in cellular processes, although its exact functions may vary across different biological contexts. Inhibitors targeting KLHDC10 are developed to bind to the protein, altering its conformation or steric environment, thereby reducing its ability to engage in normal biological functions. These interactions can occur at the active site of the protein or at allosteric sites, which are regions of the protein distinct from the active site but still capable of impacting the protein's function when bound by an inhibitor. The binding of these inhibitors to KLHDC10 can lead to the destabilization of protein-protein interactions, prevention of substrate binding, or interference with the protein's normal conformational dynamics. This specific inhibition is critical as it allows for the examination of the protein's role in various pathways without the confounding effects of broad-spectrum inhibition that might affect multiple proteins simultaneously.
To comprehend the full scope of KLHDC10 inhibitors' mechanisms of action, it's essential to consider the pathways and processes in which KLHDC10 is implicated. These inhibitors are often characterized by their ability to interfere with the protein's part in ubiquitin-mediated pathways, where KLHDC10 might be involved in tagging certain proteins for degradation. By preventing KLHDC10 from fulfilling its role, these inhibitors can stabilize proteins that would otherwise be marked for degradation, which can have a downstream impact on cellular signaling and function. The specificity of these inhibitors is paramount, as it allows for the dissection of KLHDC10's activities and the elucidation of its role within these cellular pathways. Through the inhibition of KLHDC10, researchers gain insights into the protein's contribution to cellular homeostasis and its potential involvement in the pathogenesis of various conditions, which can pave the way for further molecular and cellular understanding.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases. Since KLHDC10 is a protein that may be involved in ubiquitination processes, staurosporine would indirectly inhibit KLHDC10 activity by preventing phosphorylation events that are necessary for its function. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG132 is a proteasome inhibitor that can lead to the accumulation of ubiquitinated proteins. This accumulation might impede the function of ubiquitin-related proteins like KLHDC10 by overwhelming the degradation pathways in which KLHDC10 is potentially involved. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor that could disrupt the degradation of polyubiquitinated proteins, potentially affecting the functional role of KLHDC10 in the ubiquitin-proteasome system by inhibiting the degradation pathway where KLHDC10 may operate. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $188.00 $575.00 | 60 | |
Lactacystin is another proteasome inhibitor that can inhibit the degradation of ubiquitinated proteins. This inhibition could indirectly decrease the functional activity of KLHDC10 by disrupting the proteasomal pathway where it may be active. | ||||||
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | $137.00 $219.00 $449.00 $506.00 | 19 | |
Epoxomicin is a selective proteasome inhibitor. By blocking the proteasomal degradation pathway, it could indirectly inhibit the activity of KLHDC10 by preventing the turnover of proteins that KLHDC10 may be involved in ubiquitinating. | ||||||
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $37.00 $69.00 $109.00 $218.00 $239.00 $879.00 $1968.00 | 47 | |
Curcumin has been shown to inhibit the proteasome, which could lead to an increase in ubiquitinated proteins. This could indirectly affect the function of KLHDC10 by disrupting the cellular processes that rely on ubiquitin signaling where KLHDC10 is active. | ||||||
Withaferin A | 5119-48-2 | sc-200381 sc-200381A sc-200381B sc-200381C | 1 mg 10 mg 100 mg 1 g | $130.00 $583.00 $4172.00 $20506.00 | 20 | |
Withaferin A is a steroidal lactone that has been shown to inhibit the proteasomal pathway. This inhibition could lead to an indirect reduction of KLHDC10 activity by interfering with the degradation of ubiquitinated proteins. | ||||||
Ubiquitin E1 Inhibitor, PYR-41 | 418805-02-4 | sc-358737 | 25 mg | $360.00 | 4 | |
Pyr-41 is a ubiquitin-activating enzyme E1 inhibitor, which would impede the ubiquitination process at its earliest stage. This could indirectly affect the activity of KLHDC10 by reducing the ubiquitination that KLHDC10 relies on for its function. | ||||||
Oprozomib | 935888-69-0 | sc-477447 | 2.5 mg | $280.00 | ||
Oprozomib is an oral proteasome inhibitor that blocks the breakdown of polyubiquitinated proteins. Consequently, this could indirectly inhibit the activity of KLHDC10 by affecting the proteasomal degradation of proteins it may be involved with. | ||||||